Neuphoria Therapeutics operates as a high-risk, pre-revenue clinical entity whose financial stability is entirely contingent upon sporadic, non-recurring licensing milestones rather than sustainable commercial operations. While the company maintains a high cur...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Sep 18, 2026 | -$0.56+0.0% vs -$0.56 | $1M+17.4% vs $996,483 |
Q4 2026 Sep 2, 2026 | -$0.56+0.0% vs -$0.56 | $1M+0.0% vs $1M |
Q2 2026 May 15, 2026 | -$0.09+83.9% vs -$0.56 | — vs — |
Q1 2026 Feb 17, 2026 | -$0.77-37.5% vs -$0.56 | — vs — |
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Neuphoria Therapeutics Inc. (NASDAQ: NEUP) and Scancell Holdings plc. Upon closing
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Neuphoria Therapeutics Inc. (NASDAQ: NEUP) and Scancell Holdings plc. Upon closing of the proposed transaction, Neuphoria shareholders will own 14.5% of the combined company.Halper Sadeh encourages Neuphoria shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or zhalper@halp.
Benchmark NEUP against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Neuphoria Therapeutics Inc. (NEUP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.47 | $18.78M | -15.09 | — | -2.36% | -1.59% | — | |
| $19.95 | $3.42B | 8.71 | 11.87% | 33.42% | 32.39% | — | |
| $20.50 | $1.51B | 6.21 | 18.52% | 80.56% | 30.03% | — | |
| $295.51 | $8.24B | -21.92 | -100% | — | -34.15% | — | |
| $219.88 | $32.49B | 24.90 | 1.39% | 8.39% | 4.52% | — | |
| $41.75 | $7B | 29.20 | -5.25% | 3.96% | 3.72% | — |
Neuphoria Therapeutics Inc. (NEUP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Neuphoria Therapeutics Inc. (NEUP) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 26, 2026·SEC
Jan 8, 2026·SEC
Dec 18, 2025·SEC
Get notified when NEUP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Neuphoria Therapeutics Inc. (NEUP) stock FAQ — growth, dividends, profitability & financials explained
Neuphoria Therapeutics Inc. (NEUP) reported $1.2M in revenue for fiscal year 2025.
Neuphoria Therapeutics Inc. (NEUP) reported a net loss of $17.6M for fiscal year 2025.
Neuphoria Therapeutics Inc. (NEUP) has a return on equity (ROE) of -1.6%. Negative ROE indicates the company is unprofitable.
Neuphoria Therapeutics Inc. (NEUP) had negative free cash flow of $12.35B in fiscal year 2025, likely due to heavy capital investments.
